Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.
Adult
Aged
Betacoronavirus
Biomarkers
/ blood
Blood Chemical Analysis
C-Reactive Protein
/ metabolism
COVID-19
Cardiovascular Diseases
/ diagnosis
Cause of Death
China
/ epidemiology
Cohort Studies
Comorbidity
Coronavirus Infections
/ diagnosis
Databases, Factual
Disease Outbreaks
/ statistics & numerical data
Disease Progression
Female
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ diagnosis
Reference Values
Retrospective Studies
SARS-CoV-2
Survival Analysis
Tomography, X-Ray Computed
/ methods
COVID-19
Cardiovascular disease
Prognosis
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474
Informations de publication
Date de publication:
25 06 2020
25 06 2020
Historique:
received:
02
04
2020
revised:
08
04
2020
accepted:
08
04
2020
pubmed:
28
5
2020
medline:
1
7
2020
entrez:
28
5
2020
Statut:
ppublish
Résumé
A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19. Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including α-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), γ-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD. Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.
Sections du résumé
BACKGROUND AND AIM
A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19.
METHODS AND RESULTS
Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including α-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), γ-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD.
CONCLUSIONS
Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.
Identifiants
pubmed: 32456948
pii: S0939-4753(20)30134-4
doi: 10.1016/j.numecd.2020.04.013
pmc: PMC7165120
pii:
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1067Informations de copyright
Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflicts of interest to note.
Références
N Engl J Med. 2015 Apr 2;372(14):1333-41
pubmed: 25830423
JAMA. 2003 Jun 4;289(21):2801-9
pubmed: 12734147
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cytokine. 2018 Apr;104:8-13
pubmed: 29414327
Am J Public Health. 2019 Sep;109(9):1288-1293
pubmed: 31318592
Lancet Infect Dis. 2013 Sep;13(9):752-61
pubmed: 23891402
Circ Res. 2016 Apr 15;118(8):1313-26
pubmed: 27081112
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Sci Rep. 2017 Sep 12;7(1):11307
pubmed: 28900101
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Postgrad Med J. 2006 Feb;82(964):140-4
pubmed: 16461478
Circ Res. 2019 Mar;124(5):747-756
pubmed: 30727837
Int J Infect Dis. 2016 Aug;49:129-33
pubmed: 27352628
Radiology. 2004 Mar;230(3):836-44
pubmed: 14990845
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885